Revenue was up 15% to £7.4m including international sales up 26% to £2.4m, pre-tax profit before share based payments up 57% to £1.1m and basic EPS up 85% to 1.91p.
The Group finished the period with net cash of £2.9m (2013: £1.5m)
Tristel’s lead technology is a proprietary Chlorine dioxide formulation addressing three distinct markets:
- The Human Healthcare market (hospital infection prevention - via the Tristel brand)
- The Contamination Control market (control of contamination in critical environments - via the Crystel brand)
- The Animal Healthcare market (veterinary practice infection prevention - via the Anistel brand)
The significant capital investment over the past few years, including £400,000 in creating 20,000 sq ft of new factory, office and warehouse space which was officially opened on 2nd October 2014 puts the business in great shape to support further growth.
The Group’s proprietary technology that is supported by widespread patent protection covering two-thirds of…
Register to continue reading this article.
Already a member? Login
For access to the top news and insights from the investment worldREGISTER FREE TODAY
It’s not always easy to keep track of your investments. Sometimes big news gets hidden in…
The value of Tristel’s medical device decontamination products are highlighted by the fact that the company…